

Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

Claims 1-21. (Cancelled).

Claim 22 (New): A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering 2 to 8 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form and a sub-maximal amount of an insulin secretagogue, to a mammal in need thereof.

Claim 23 (New): A method according to claim 22, wherein the insulin secretagogue is a sulphonylurea.

Claim 24 (New): A method according to claim 22, wherein the insulin secretagogue is selected from the group consisting of glibenclamide, glipizide, gliclazide, glimepiride, tolazamide, tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glycopyamide, glycylamide, and repaglinide.

Claim 25 (New): A method according to claim 22, which comprises administering a unit dosage form comprising 1, 2, 3, 4, 5, 6, 7 or 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, from 1 to 2 times per day.

Claim 26 (New): A method according to claim 25, wherein said unit dosage form is a tablet or a capsule.

Claim 27 (New): A method according to claim 22, which comprises co-administering said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and said insulin secretagogue.

Claim 28 (New): A method according to claim 27, which comprises administering a formulation which comprises both of said 5-[4-[2-(N-methyl-N-(2-

pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and said insulin secretagogue.

Claim 29 (New): A method according to claim 27, which comprises administration of separate formulations of each of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and said insulin secretagogue.

Claim 30 (New): A method according to claim 22, which comprises sequential administration of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and said insulin secretagogue.

Claim 31 (New): A method according to claim 22, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

Claim 42 (New): A method according to claim 31, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 33 (New): A method according to claim 22, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

Claim 34 (New): A method according to claim 22, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 35 (New): A method according to claim 33, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 36 (New): A method according to claim 34, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 37 (New): A method according to claim 22, which comprises administering a tablet or a capsule comprising 1 to 8 mg of said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and glimepiride.

Claim 38 (New): A method for treatment of Type II diabetes mellitus in a mammal, which method comprises administering 2 to 8 mg per day of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, and a sub-maximal amount of an insulin secretagogue, to a mammal in need thereof.

Claim 39 (New): A pharmaceutical composition comprising 1, 2, 4 or 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, a sub-maximal amount of an insulin secretagogue, and a pharmaceutically acceptable carrier therefor.

Claim 40 (New): A pharmaceutical composition according to claim 39, wherein said insulin secretagogue is a glimepiride.

Claim 41 (New): A pharmaceutical composition according to claim 39, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable salt form.

Claim 42 (New): A pharmaceutical composition according to claim 41, wherein said pharmaceutically acceptable salt is a maleate salt.

Claim 43 (New): A pharmaceutical composition according to claim 39, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate form.

Claim 44 (New): A pharmaceutical composition according to claim 39, wherein said pharmaceutically acceptable form is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt form.

Claim 45 (New): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 46 (New): A pharmaceutical composition according to claim 44, wherein said pharmaceutically acceptable solvate is a hydrate.

Claim 47 (New): A method according to claim 22, wherein said 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, or a tautomer thereof, in a pharmaceutically acceptable form, is administered in a pharmaceutically acceptable composition comprising sodium starch glycollate, hydroxypropyl methylcellulose, microcrystalline cellulose and lactose monohydrate.